Cited 73 times in
Bone Mineral Density After Transitioning From Denosumab to Alendronate
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이유미 | - |
dc.date.accessioned | 2020-06-17T00:33:58Z | - |
dc.date.available | 2020-06-17T00:33:58Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 0021-972X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/176029 | - |
dc.description.abstract | Context: There are few studies on patients transitioning from denosumab to bisphosphonates. Objective: To investigate patient characteristics and changes in bone mineral density (BMD) after transitioning from denosumab to alendronate. Design: Randomized, open-label, 2-year crossover Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531). Setting: 25 study centers in the US and Canada. Patients: Treatment-naïve postmenopausal women with BMD T-scores from -2.0 to -4.0. Interventions: This post hoc analysis evaluated women randomized to subcutaneous denosumab 60 mg every 6 months in year 1 followed by once-weekly oral alendronate 70 mg in year 2. Main outcome measure: A 3% BMD threshold identified participants who lost, maintained, or gained BMD in year 2 on alendronate. Results: Of 126 participants randomized to denosumab, 115 (91%) transitioned to alendronate in year 2. BMD increased by 3% to 6% with denosumab in year 1 and by 0% to 1% with alendronate in year 2. After transitioning to alendronate, most participants maintained or increased BMD; 15.9%, 7.6%, and 21.7% lost BMD at the lumbar spine, total hip, and femoral neck, respectively. Few participants fell below their pretreatment baseline BMD value; this occurred most often in those who lost BMD in year 2. Women who lost BMD with alendronate in year 2 also showed a greater percent change in BMD with denosumab in year 1. The BMD change in year 2 was similar regardless of baseline characteristics or adherence to oral alendronate. Conclusion: Alendronate can effectively maintain the BMD gains accrued after 1 year of denosumab in most patients, regardless of baseline characteristics. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Endocrine Society | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Bone Mineral Density After Transitioning From Denosumab to Alendronate | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | David Kendler | - |
dc.contributor.googleauthor | Arkadi Chines | - |
dc.contributor.googleauthor | Patricia Clark | - |
dc.contributor.googleauthor | Peter R Ebeling | - |
dc.contributor.googleauthor | Michael McClung | - |
dc.contributor.googleauthor | Yumie Rhee | - |
dc.contributor.googleauthor | Shuang Huang | - |
dc.contributor.googleauthor | Robert Kees Stad | - |
dc.identifier.doi | 10.1210/clinem/dgz095 | - |
dc.contributor.localId | A03012 | - |
dc.relation.journalcode | J01318 | - |
dc.identifier.eissn | 1945-7197 | - |
dc.identifier.pmid | 31665314 | - |
dc.subject.keyword | alendronate | - |
dc.subject.keyword | bisphosphonates | - |
dc.subject.keyword | bone mineral density | - |
dc.subject.keyword | denosumab | - |
dc.subject.keyword | osteoporosis | - |
dc.contributor.alternativeName | Rhee, Yumie | - |
dc.contributor.affiliatedAuthor | 이유미 | - |
dc.citation.volume | 105 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | e255 | - |
dc.citation.endPage | e264 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, Vol.105(3) : e255-e264, 2020-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.